Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Association of CD2AP neuronal deposits with Braak neurofibrillary stage in Alzheimer’s disease

  • Camacho Soriano, Jessica
  • Rábano, Alberto
  • Marazuela Fuentes, Paula
  • Bonaterra Pastra, Anna
  • Serna Alonso, Garazi
  • Moline Marimon, Teresa
  • Ramon y Cajal Agüeras, Santiago
  • Martinez Saez, Elena Antima
  • Hernandez Guillamon, Maria Mar
Alzheimer; CD2AP; Enfermedad de Pick, Alzheimer's disease; CD2AP; Pick's disease, Alzheimer; CD2AP; Malaltia de Pick, Genome-wide association studies have described several genes as genetic susceptibility loci for Alzheimer's disease (AD). Among them, CD2AP encodes CD2-associated protein, a scaffold protein implicated in dynamic actin remodeling and membrane trafficking during endocytosis and cytokinesis. Although a clear link between CD2AP defects and glomerular pathology has been described, little is known about the function of CD2AP in the brain. The aim of this study was to analyze the distribution of CD2AP in the AD brain and its potential associations with tau aggregation and β-amyloid (Aβ) deposition. First, we performed immunohistochemical analysis of CD2AP expression in brain tissue from AD patients and controls (N = 60). Our results showed granular CD2AP immunoreactivity in the human brain endothelium in all samples. In AD cases, no CD2AP was found to be associated with Aβ deposits in vessels or parenchymal plaques. CD2AP neuronal inclusions similar to neurofibrillary tangles (NFT) and neuropil thread-like deposits were found only in AD samples. Moreover, immunofluorescence analysis revealed that CD2AP colocalized with pTau. Regarding CD2AP neuronal distribution, a hierarchical progression from the entorhinal to the temporal and occipital cortex was detected. We found that CD2AP immunodetection in neurons was strongly and positively associated with Braak neurofibrillary stage, independent of age and other pathological hallmarks. To further investigate the association between pTau and CD2AP, we included samples from cases of primary tauopathies (corticobasal degeneration [CBD], progressive supranuclear palsy [PSP], and Pick's disease [PiD]) in our study. Among these cases, CD2AP positivity was only found in PiD samples as neurofibrillary tangle-like and Pick body-like deposits, whereas no neuronal CD2AP deposits were detected in PSP or CBD samples, which suggested an association of CD2AP neuronal expression with 3R-Tau-diseases. In conclusion, our findings open a new road to investigate the complex cellular mechanism underlying the tangle conformation and tau pathology in the brain., This work was funded by Instituto de Salud Carlos III (ISCIII) (PI17/00275, PI20/00465), cofinanced by the European Regional Development Fund (FEDER). The Neurovascular Research Laboratory is part of the INVICTUS+ network, ISCIII, Spain (RD16/0019/0021). M.H.-G. is supported by the Miguel Servet Programme, ISCIII, Spain (CPII17/00010)
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Comparison of Plasma Lipoprotein Composition and Function in Cerebral Amyloid Angiopathy and Alzheimer’s Disease

  • Bonaterra Pastra, Anna
  • Fernández de Retana, Sofía
  • Rivas-Urbina, Andrea
  • Puig, Núria
  • Benítez, Sònia
  • Pancorbo Rosal, Olalla
  • Rodriguez Luna, David
  • Pujadas Navinés, Francesc
  • Montaner Villalonga, Joan
  • Hernandez Guillamon, Maria Mar
Malaltia d'Alzheimer; Apolipoproteïnes; Angiopatia amiloide cerebral, Enfermedad de Alzheimer; Apolipoproteínas; Angiopatía amiloide cerebral, Alzheimer’s disease; Apolipoproteins; Cerebral amyloid angiopathy, Cerebral amyloid angiopathy (CAA) refers to beta-amyloid (Aβ) deposition in brain vessels and is clinically the main cause of lobar intracerebral hemorrhage (ICH). Aβ can also accumulate in brain parenchyma forming neuritic plaques in Alzheimer’s disease (AD). Our study aimed to determine whether the peripheral lipid profile and lipoprotein composition are associated with cerebral beta-amyloidosis pathology and may reflect biological differences in AD and CAA. For this purpose, lipid and apolipoproteins levels were analyzed in plasma from 51 ICH-CAA patients (collected during the chronic phase of the disease), 60 AD patients, and 60 control subjects. Lipoproteins (VLDL, LDL, and HDL) were isolated and their composition and pro/antioxidant ability were determined. We observed that alterations in the lipid profile and lipoprotein composition were remarkable in the ICH-CAA group compared to control subjects, whereas the AD group presented no specific alterations compared with controls. ICH-CAA patients presented an atheroprotective profile, which consisted of lower total and LDL cholesterol levels. Plasma from chronic ICH-CAA patients also showed a redistribution of ApoC-III from HDL to VLDL and a higher ApoE/ApoC-III ratio in HDL. Whether these alterations reflect a protective response or have a causative effect on the pathology requires further investigation., This research was funded by Instituto de Salud Carlos III (co-financed by the European Regional Development Fund FEDER “Una manera de hacer Europa”), grant numbers PI13/00364, PI16/00471, PI14/01134 and PI17/00275. A.R.-U. was funded by Instituto de Salud Carlos III predoctoral contract FI17/00031. The Neurovascular Research Laboratory is part of the INVICTUS+ network, ISCIII, Spain [RD16/0019/0021]. J.L.S.-Q. is a member of the CIBER of Diabetes and Metabolism (CIBERDEM), ISCIII, Spain. M.H.-G. is supported by the Miguel Servet programme, ISCIII, Spain [CPII17/00010]. A.R.-U., N.P., S.B. and J.L.S.-Q. are members of the Quality Research Group 2017-SGR-1149 from Generalitat de Catalunya. A.R.-U., N.P., S.B. and J.L.S.-Q. are members of the Group of Vascular Biology from the Spanish Atherosclerosis Society.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Circulating AQP4 Levels in Patients with Cerebral Amyloid Angiopathy-Associated Intracerebral Hemorrhage

  • Marazuela Fuentes, Paula
  • Bonaterra Pastra, Anna
  • Faura Llorens, Julia
  • Penalba Morenilla, Anna
  • Pizarro Gonzálvez, Jesús
  • Pancorbo Rosal, Olalla
  • Rodriguez Luna, David
  • Vert Soler, Carla
  • Rovira Cañellas, Alex
  • Pujadas Navinés, Francesc
  • Montaner Villalonga, Joan
  • Delgado Martínez, Maria Pilar
  • Hernandez Guillamon, Maria Mar
Aquaporina 4; Angiopatia amiloide cerebral; Marcadors d'imatge per ressonància magnètica, Acuaporina 4; Angiopatía amiloide cerebral; Marcadores de imágenes por resonancia magnética, Aquaporin 4; Cerebral amyloid angiopathy; Magnetic resonance imaging markers, Cerebral amyloid angiopathy (CAA) is a major cause of lobar intracerebral hemorrhage (ICH) in elderly patients. Growing evidence suggests a potential role of aquaporin 4 (AQP4) in amyloid-beta-associated diseases, including CAA pathology. Our aim was to investigate the circulating levels of AQP4 in a cohort of patients who had suffered a lobar ICH with a clinical diagnosis of CAA. AQP4 levels were analyzed in the serum of 60 CAA-related ICH patients and 19 non-stroke subjects by enzyme-linked immunosorbent assay (ELISA). The CAA–ICH cohort was divided according to the time point of the functional outcome evaluation: mid-term (12 ± 18.6 months) and long-term (38.5 ± 32.9 months) after the last ICH. Although no differences were found in AQP4 serum levels between cases and controls, lower levels were found in CAA patients presenting specific hemorrhagic features such as ≥2 lobar ICHs and ≥5 lobar microbleeds detected by magnetic resonance imaging (MRI). In addition, CAA-related ICH patients who presented a long-term good functional outcome had higher circulating AQP4 levels than subjects with a poor outcome or controls. Our data suggest that AQP4 could potentially predict a long-term functional outcome and may play a protective role after a lobar ICH., This research was funded by the Instituto de Salud Carlos III (ISCIII), (PI17/00275 and PI20/00465), co-financed by the European Regional Development Fund FEDER. The Neurovascular Research Laboratory is part of the INVICTUS+ network, ISCIII, Spain (RD16/0019/0021). M.H.-G. was supported by the Miguel Servet programme, ISCIII, Spain (CPII17/00010). P.M. held a predoctoral fellowship from the Vall d’Hebron Research Institute.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Peripheral administration of human recombinant ApoJ/clusterin modulates brain beta-amyloid levels in APP23 mice

  • Fernández-de-Retana, Sofía|||0000-0002-6350-8640
  • Marazuela, Paula|||0000-0003-1038-5242
  • Solé Piñol, Montserrat|||0000-0003-4240-6562
  • Colell, Guillem
  • Bonaterra-Pastra, Anna|||0000-0002-1480-622X
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Montaner, Joan|||0000-0003-4845-2279
  • Maspoch, Daniel|||0000-0003-1325-9161
  • Cano-Sarabia, Mary|||0000-0003-4254-8157
  • Hernández Guillamón, Maria Mar
Background: ApoJ/clusterin is a multifunctional protein highly expressed in the brain. The implication of ApoJ in β-amyloid (Aβ) fibrillization and clearance in the context of Alzheimer's disease has been widely studied, although the source and concentration of ApoJ that promotes or inhibits Aβ cerebral accumulation is not clear yet. ApoJ is abundant in plasma and approximately 20% can appear bound to HDL-particles. In this regard, the impact of plasmatic ApoJ and its lipidation status on cerebral β-amyloidosis is still not known. Hence, our main objective was to study the effect of a peripheral increase of free ApoJ or reconstituted HDL particles containing ApoJ in an experimental model of cerebral β-amyloidosis. Methods: Fourteen-month-old APP23 transgenic mice were subjected to subchronic intravenous treatment with rHDL-rApoJ nanodiscs or free rApoJ for 1 month. Aβ concentration and distribution in the brain, as well as Aβ levels in plasma and CSF, were determined after treatments. Other features associated to AD pathology, such as neuronal loss and neuroinflammation, were also evaluated. Results: Both ApoJ-based treatments prevented the Aβ accumulation in cerebral arteries and induced a decrease in total brain insoluble Aβ levels. The peripheral treatment with rApoJ also induced an increase in the Aβ levels in CSF, whereas the concentration remained unaltered in plasma. At all the endpoints studied, the lipidation of rApoJ did not enhance the protective properties of free rApoJ. The effects obtained after subchronic treatment with free rApoJ were accompanied by a reduction in hippocampal neuronal loss and an enhancement of the expression of a phagocytic marker in microglial cells surrounding Aβ deposits. Finally, despite the activation of this phagocytic phenotype, treatments did not induce a global neuroinflammatory status. In fact, free rApoJ treatment was able to reduce the levels of interleukin-17 (IL17) and keratinocyte chemoattractant (KC) chemokine in the brain. Conclusions: Our results demonstrate that an increase in circulating human rApoJ induces a reduction of insoluble Aβ and CAA load in the brain of APP23 mice. Thus, our study suggests that peripheral interventions, based on treatments with multifunctional physiological chaperones, offer therapeutic opportunities to regulate the cerebral Aβ load.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Brain ApoA-I, ApoJ and ApoE immunodetection in cerebral amyloid angiopathy

  • Camacho, Jessica|||0000-0001-8018-8274
  • Moliné, Teresa|||0000-0003-4912-5114
  • Bonaterra-Pastra, Anna|||0000-0002-1480-622X
  • Ramón y Cajal, Santiago|||0000-0002-3867-1390
  • Martinez-Saez, Elena|||0000-0001-6004-5364
  • Hernandez Guillamon, Maria Mar|||0000-0001-8844-0091
Cerebral amyloid angiopathy (CAA) is a common cause of lobar intracerebral hemorrhage (ICH) in elderly individuals and it is the result of the cerebrovascular deposition of beta-amyloid (Ab) protein. CAA is frequently found in patients with Alzheimer's disease (AD), although it has an independent contribution to the cognitive deterioration associated with age. Specific apolipoproteins (Apo) have been associated with Ab fibrillization and clearance from the brain. In this regard, in the present study, we analyzed the brain levels of ApoE, ApoA-I, and ApoJ/clusterin in autopsy brains from 20 post-mortem cases with CAA type I, CAA type II, with parenchymal Ab deposits or without Aβ deposits. Our objective was to find a possible differential pattern of apolipoproteins distribution in the brain depending on the CAA pathological presentation. The protein expression levels were adjusted by the APOE genotype of the patients included in the study. We found that ApoE and ApoJ were abundantly present in meningeal, cortical, and capillary vessels of the brains with vascular Aβ accumulation. ApoE and ApoJ also deposited extracellularly in the parenchyma, especially in cases presenting Aβ diffuse and neuritic parenchymal deposits. In contrast, ApoA-I staining was only relevant in capillary walls in CAA type I cases. On the other hand, ICH was the principal cause of death among CAA patients in our cohort. We found that CAA patients with ICH more commonly had APOE+2 compared with CAA patients without ICH. In addition, patients who suffered an ICH presented higher vascular ApoE levels in brain. However, higher ApoE presence in cortical arteries was the only independent predictor of suffering an ICH in our cohort after adjusting by age and APOE genotype. In conclusion, while ApoE and ApoJ appear to be involved in both vascular and parenchymal Ab pathology, ApoA-I seems to be mainly associated with CAA, especially in CAA type I pathology. We consider that our study helps to molecularly characterize the distribution subtypes of Aβ deposition within the brain.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Comparison of plasma lipoprotein composition and function in cerebral amyloid angiopathy and Alzheimer's disease

  • Bonaterra-Pastra, Anna|||0000-0002-1480-622X
  • Fernández-de-Retana, Sofía|||0000-0002-6350-8640
  • Rivas-Urbina, Andrea|||0000-0002-0111-0477
  • Puig Grifol, Núria|||0000-0002-4699-3162
  • Benitez, Sonia|||0000-0003-3565-0743
  • Pancorbo, Olalla|||0000-0003-3240-4862
  • Rodriguez-Luna, David|||0000-0001-8053-4536
  • Pujadas, Francesc|||0000-0003-3569-2601
  • Freijo, Maria del Mar
  • Tur, Silvia
  • Martinez Zabaleta, Maite
  • Cardona, Pere-Joan|||0000-0001-5623-7873
  • Vera, Rocío
  • Lebrato-Hernández, Lucia|||0000-0002-3541-0697
  • Arenillas, Juan F.|||0000-0001-7464-6101
  • Pérez-Sánchez, Soledad|||0000-0002-8940-9763
  • Montaner, Joan|||0000-0003-4845-2279
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Hernandez Guillamon, Maria Mar|||0000-0001-8844-0091
Cerebral amyloid angiopathy (CAA) refers to beta-amyloid (Aβ) deposition in brain vessels and is clinically the main cause of lobar intracerebral hemorrhage (ICH). Aβ can also accumulate in brain parenchyma forming neuritic plaques in Alzheimer's disease (AD). Our study aimed to determine whether the peripheral lipid profile and lipoprotein composition are associated with cerebral beta-amyloidosis pathology and may reflect biological differences in AD and CAA. For this purpose, lipid and apolipoproteins levels were analyzed in plasma from 51 ICH-CAA patients (collected during the chronic phase of the disease), 60 AD patients, and 60 control subjects. Lipoproteins (VLDL, LDL, and HDL) were isolated and their composition and pro/antioxidant ability were determined. We observed that alterations in the lipid profile and lipoprotein composition were remarkable in the ICH-CAA group compared to control subjects, whereas the AD group presented no specific alterations compared with controls. ICH-CAA patients presented an atheroprotective profile, which consisted of lower total and LDL cholesterol levels. Plasma from chronic ICH-CAA patients also showed a redistribution of ApoC-III from HDL to VLDL and a higher ApoE/ApoC-III ratio in HDL. Whether these alterations reflect a protective response or have a causative effect on the pathology requires further investigation.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Circulating AQP4 Levels in Patients with Cerebral Amyloid Angiopathy-Associated Intracerebral Hemorrhage

  • Marazuela, Paula|||0000-0003-1038-5242
  • Bonaterra-Pastra, Anna|||0000-0002-1480-622X
  • Faura, Júlia|||0000-0002-8436-1377
  • Penalba, Anna
  • Pizarro Gonzálvez, Jesús|||0000-0002-5808-9293
  • Pancorbo, Olalla|||0000-0003-3240-4862
  • Rodriguez-Luna, David|||0000-0001-8053-4536
  • Vert, Carla
  • Rovira, Alex|||0000-0002-2132-6750
  • Pujadas, Francesc|||0000-0003-3569-2601
  • Freijo, M. Mar
  • Tur, Silvia
  • Martínez-Zabaleta, Maite
  • Cardona, Pere-Joan|||0000-0001-5623-7873
  • Vera, Rocío
  • Lebrato-Hernández, Lucia|||0000-0002-3541-0697
  • Arenillas, Juan F.|||0000-0001-7464-6101
  • Pérez-Sánchez, Soledad|||0000-0002-8940-9763
  • Montaner, Joan|||0000-0003-4845-2279
  • Delgado Martínez, María Pilar|||0000-0002-1628-4488
  • Hernandez Guillamon, Maria Mar|||0000-0001-8844-0091
Cerebral amyloid angiopathy (CAA) is a major cause of lobar intracerebral hemorrhage (ICH) in elderly patients. Growing evidence suggests a potential role of aquaporin 4 (AQP4) in amyloid-beta-associated diseases, including CAA pathology. Our aim was to investigate the circulating levels of AQP4 in a cohort of patients who had suffered a lobar ICH with a clinical diagnosis of CAA. AQP4 levels were analyzed in the serum of 60 CAA-related ICH patients and 19 non-stroke subjects by enzyme-linked immunosorbent assay (ELISA). The CAA-ICH cohort was divided according to the time point of the functional outcome evaluation: mid-term (12 ± 18.6 months) and long-term (38.5 ± 32.9 months) after the last ICH. Although no differences were found in AQP4 serum levels between cases and controls, lower levels were found in CAA patients presenting specific hemorrhagic features such as ≥2 lobar ICHs and ≥5 lobar microbleeds detected by magnetic resonance imaging (MRI). In addition, CAA-related ICH patients who presented a long-term good functional outcome had higher circulating AQP4 levels than subjects with a poor outcome or controls. Our data suggest that AQP4 could potentially predict a long-term functional outcome and may play a protective role after a lobar ICH.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Association of CD2AP neuronal deposits with Braak neurofibrillary stage in Alzheimer’s disease

  • Camacho Soriano, Jessica
  • Rábano, Alberto
  • Marazuela Fuentes, Paula
  • Bonaterra Pastra, Anna
  • Serna Alonso, Garazi
  • Moline Marimon, Teresa
  • Ramon y Cajal Agüeras, Santiago
  • Martinez Saez, Elena Antima
  • Hernandez Guillamon, Maria Mar
Alzheimer; CD2AP; Enfermedad de Pick, Alzheimer's disease; CD2AP; Pick's disease, Alzheimer; CD2AP; Malaltia de Pick, Genome-wide association studies have described several genes as genetic susceptibility loci for Alzheimer's disease (AD). Among them, CD2AP encodes CD2-associated protein, a scaffold protein implicated in dynamic actin remodeling and membrane trafficking during endocytosis and cytokinesis. Although a clear link between CD2AP defects and glomerular pathology has been described, little is known about the function of CD2AP in the brain. The aim of this study was to analyze the distribution of CD2AP in the AD brain and its potential associations with tau aggregation and β-amyloid (Aβ) deposition. First, we performed immunohistochemical analysis of CD2AP expression in brain tissue from AD patients and controls (N = 60). Our results showed granular CD2AP immunoreactivity in the human brain endothelium in all samples. In AD cases, no CD2AP was found to be associated with Aβ deposits in vessels or parenchymal plaques. CD2AP neuronal inclusions similar to neurofibrillary tangles (NFT) and neuropil thread-like deposits were found only in AD samples. Moreover, immunofluorescence analysis revealed that CD2AP colocalized with pTau. Regarding CD2AP neuronal distribution, a hierarchical progression from the entorhinal to the temporal and occipital cortex was detected. We found that CD2AP immunodetection in neurons was strongly and positively associated with Braak neurofibrillary stage, independent of age and other pathological hallmarks. To further investigate the association between pTau and CD2AP, we included samples from cases of primary tauopathies (corticobasal degeneration [CBD], progressive supranuclear palsy [PSP], and Pick's disease [PiD]) in our study. Among these cases, CD2AP positivity was only found in PiD samples as neurofibrillary tangle-like and Pick body-like deposits, whereas no neuronal CD2AP deposits were detected in PSP or CBD samples, which suggested an association of CD2AP neuronal expression with 3R-Tau-diseases. In conclusion, our findings open a new road to investigate the complex cellular mechanism underlying the tangle conformation and tau pathology in the brain., This work was funded by Instituto de Salud Carlos III (ISCIII) (PI17/00275, PI20/00465), cofinanced by the European Regional Development Fund (FEDER). The Neurovascular Research Laboratory is part of the INVICTUS+ network, ISCIII, Spain (RD16/0019/0021). M.H.-G. is supported by the Miguel Servet Programme, ISCIII, Spain (CPII17/00010)
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Circulating AQP4 Levels in Patients with Cerebral Amyloid Angiopathy-Associated Intracerebral Hemorrhage

  • Marazuela Fuentes, Paula
  • Bonaterra Pastra, Anna
  • Faura Llorens, Julia
  • Penalba Morenilla, Anna
  • Pizarro Gonzálvez, Jesús
  • Pancorbo Rosal, Olalla
  • Rodriguez Luna, David
  • Vert Soler, Carla
  • Rovira, Alex
  • Pujadas Navinés, Francesc
  • Montaner Villalonga, Joan
  • Delgado Martínez, Maria Pilar
  • Hernandez Guillamon, Maria Mar
Aquaporina 4; Angiopatia amiloide cerebral; Marcadors d'imatge per ressonància magnètica, Acuaporina 4; Angiopatía amiloide cerebral; Marcadores de imágenes por resonancia magnética, Aquaporin 4; Cerebral amyloid angiopathy; Magnetic resonance imaging markers, Cerebral amyloid angiopathy (CAA) is a major cause of lobar intracerebral hemorrhage (ICH) in elderly patients. Growing evidence suggests a potential role of aquaporin 4 (AQP4) in amyloid-beta-associated diseases, including CAA pathology. Our aim was to investigate the circulating levels of AQP4 in a cohort of patients who had suffered a lobar ICH with a clinical diagnosis of CAA. AQP4 levels were analyzed in the serum of 60 CAA-related ICH patients and 19 non-stroke subjects by enzyme-linked immunosorbent assay (ELISA). The CAA–ICH cohort was divided according to the time point of the functional outcome evaluation: mid-term (12 ± 18.6 months) and long-term (38.5 ± 32.9 months) after the last ICH. Although no differences were found in AQP4 serum levels between cases and controls, lower levels were found in CAA patients presenting specific hemorrhagic features such as ≥2 lobar ICHs and ≥5 lobar microbleeds detected by magnetic resonance imaging (MRI). In addition, CAA-related ICH patients who presented a long-term good functional outcome had higher circulating AQP4 levels than subjects with a poor outcome or controls. Our data suggest that AQP4 could potentially predict a long-term functional outcome and may play a protective role after a lobar ICH., This research was funded by the Instituto de Salud Carlos III (ISCIII), (PI17/00275 and PI20/00465), co-financed by the European Regional Development Fund FEDER. The Neurovascular Research Laboratory is part of the INVICTUS+ network, ISCIII, Spain (RD16/0019/0021). M.H.-G. was supported by the Miguel Servet programme, ISCIII, Spain (CPII17/00010). P.M. held a predoctoral fellowship from the Vall d’Hebron Research Institute.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Comparison of Plasma Lipoprotein Composition and Function in Cerebral Amyloid Angiopathy and Alzheimer’s Disease

  • Bonaterra Pastra, Anna
  • Fernández de Retana, Sofía
  • Rivas-Urbina, Andrea
  • Puig, Núria
  • Benítez, Sònia
  • Pancorbo Rosal, Olalla
  • Rodriguez Luna, David
  • Pujadas Navinés, Francesc
  • Montaner Villalonga, Joan
  • Hernandez Guillamon, Maria Mar
Malaltia d'Alzheimer; Apolipoproteïnes; Angiopatia amiloide cerebral, Enfermedad de Alzheimer; Apolipoproteínas; Angiopatía amiloide cerebral, Alzheimer’s disease; Apolipoproteins; Cerebral amyloid angiopathy, Cerebral amyloid angiopathy (CAA) refers to beta-amyloid (Aβ) deposition in brain vessels and is clinically the main cause of lobar intracerebral hemorrhage (ICH). Aβ can also accumulate in brain parenchyma forming neuritic plaques in Alzheimer’s disease (AD). Our study aimed to determine whether the peripheral lipid profile and lipoprotein composition are associated with cerebral beta-amyloidosis pathology and may reflect biological differences in AD and CAA. For this purpose, lipid and apolipoproteins levels were analyzed in plasma from 51 ICH-CAA patients (collected during the chronic phase of the disease), 60 AD patients, and 60 control subjects. Lipoproteins (VLDL, LDL, and HDL) were isolated and their composition and pro/antioxidant ability were determined. We observed that alterations in the lipid profile and lipoprotein composition were remarkable in the ICH-CAA group compared to control subjects, whereas the AD group presented no specific alterations compared with controls. ICH-CAA patients presented an atheroprotective profile, which consisted of lower total and LDL cholesterol levels. Plasma from chronic ICH-CAA patients also showed a redistribution of ApoC-III from HDL to VLDL and a higher ApoE/ApoC-III ratio in HDL. Whether these alterations reflect a protective response or have a causative effect on the pathology requires further investigation., This research was funded by Instituto de Salud Carlos III (co-financed by the European Regional Development Fund FEDER “Una manera de hacer Europa”), grant numbers PI13/00364, PI16/00471, PI14/01134 and PI17/00275. A.R.-U. was funded by Instituto de Salud Carlos III predoctoral contract FI17/00031. The Neurovascular Research Laboratory is part of the INVICTUS+ network, ISCIII, Spain [RD16/0019/0021]. J.L.S.-Q. is a member of the CIBER of Diabetes and Metabolism (CIBERDEM), ISCIII, Spain. M.H.-G. is supported by the Miguel Servet programme, ISCIII, Spain [CPII17/00010]. A.R.-U., N.P., S.B. and J.L.S.-Q. are members of the Quality Research Group 2017-SGR-1149 from Generalitat de Catalunya. A.R.-U., N.P., S.B. and J.L.S.-Q. are members of the Group of Vascular Biology from the Spanish Atherosclerosis Society.